New graft promises better healing after skin cancer removal
NCT ID NCT06919809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a special skin graft called X A-DERM™ mADM in 16 people who had Mohs surgery to remove skin cancers like basal cell carcinoma or squamous cell carcinoma. The graft has a micro-textured surface designed to help the wound heal faster and leave a better scar. Researchers checked healing with photos and scar assessments over 60 days. The goal was to see if this graft improves recovery compared to standard methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- X A-DERM™ microsurfaced acellular dermal matrix (mADM) graft
- What this could lead to
- If it works, this could provide a better way to heal wounds and reduce scarring after skin cancer removal surgery.
- What could go wrong
- This is a very small, single-arm study with only 16 participants, so results may not apply to everyone. The device is new and may not improve healing over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
16 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects must meet all the following criteria to be entered into the study: 1. Between 18 and 85 years of age, inclusive 2. Subject in good health, or with stable treated medical condition, as determined by the investigator. 3. Scheduled to undergo elective Mohs surgery to remove a single biopsy-proven basal cell carcinoma (BCC), squamous cell carcinoma (SCC), or melanoma in situ (MIS) lesion on the head, face, or upper extremity that is amenable to Mohs surgery. 4. Tumor location and size meets the following criteria for immediate MMS: * Largest total surface area of ≤16cm2 and smallest total surface area per PI discretion. * Depth with majority of tumor excision at least to subcutaneous tissue. * Adequate dermal contract with graft. 5. Willing and able to complete and comply with procedures, protocol requirements, and instructions, including self-performed wound care and completion of all required visits. 6. Able to speak, read, write, and understand the language of the informed consent form (ICF) and study questionnaires. 7. Willingness and ability to understand the risks, benefits, and alternatives to participation, and give informed consent. \- Exclusion Criteria: Subjects who meet the above inclusion criteria will be eligible for the study, unless they present with any of the following: 1. History of wound abnormalities or any other findings that would impede participation in the trial, as per PI discretion. 2. Post-operative defects superficial and deemed not appropriate for second intention healing, as determined by the investigator. 3. Pregnant, lactating/breast feeding, or planning a pregnancy. A negative urine pregnancy test will be required at screening for female subjects of childbearing potential; a woman will be considered to be of childbearing potential unless she has had a tubal ligation, total hysterectomy, bilateral oophorectomy, or is postmenopausal (without a menstrual period for at least one year). \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCC - basal cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bare Dermatology
Rockwall, Texas, 75032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a glowing drug light up head and neck tumors?
- Needle-Free light therapy shows promise for common skin cancer
- New imaging tool may help detect Eye-Area skin cancer without a biopsy
- Smartphone screening could catch skin cancer sooner
- Blue dye gel shows promise for treating inoperable skin cancer
- Blood test may predict cancer recurrence in head and neck patients